New drug HRS-1893 tested for Long-Term safety in heart disease patients

NCT ID NCT07021963

Recruiting now Disease control Sponsor: Shandong Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study is checking the long-term safety of a drug called HRS-1893 in 300 people with hypertrophic cardiomyopathy, a condition where the heart muscle thickens. Participants have already taken HRS-1893 in earlier studies. The main goal is to see how many side effects occur and if the heart's pumping function stays normal.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-1893 tablet
What this could lead to: If successful, this could show that HRS-1893 is safe enough to use long-term for managing hypertrophic cardiomyopathy, potentially leading to a new treatment option.
What could go wrong: This is an early-phase study focused on safety, not effectiveness. It may not prove the drug works, and side effects or heart function declines could occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTROPHIC CARDIOMYOPATHY

Contacts and locations

Locations

Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
RECRUITING

Beijing, Beijing Municipality, 100037, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.